Thyroid Eye Disease (TED) Clinical Trials
RECRUITING: A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease.
https://clinicaltrials.gov/study/NCT06248619?term=NCT06248619&rank=1
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED). The first international approval outside of the U.S.
FDA expands teprotumumab indication to include any thyroid eye disease duration, activity.
Research presented at the American Society of Ophthalmic, Plastic, and Reconstructive Surgery annual meeting noted a decrease in eye muscle size for patients with TED who underwent treatment with TEPEZZA (TM), resulting in better eye movement and less double vision.
UplighTED Clinical Trial Website
Use this link to see if you qualify for this Clinical Trial
Condition – Thyroid Eye Disease
Official Title – A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants with Thyroid Eye Disease
Intervention – Combination Product: Efgartigimod PH20SC and Placebo
Delivery – subcutaneous injection
Total Number of treatments – 24 weeks; Open-Label Extension study available
Time between treatments – 1 week
Recruiting – Now
Recruiting – 108 participants
NCT Number: NCT06307626
EU Trial (CTIS) Number: 2023-509198-22-00
Study Name: UplighTED – ARGX – 113-2301; ARGX – 113-2309
ACELYRIN is currently recruiting for a clinical study designed to evaluate lonigutamab in subjects with TED. Use this link to learn more.
-
- REVEAL-1
- Phase 3 clinical trial to evaluate the potential benefits and safety of the subcutaneously administered investigational drug VRDN-003 for people affected by active TED
- https://clinicaltrials.gov/study/NCT06625411
- Recruiting participants
- REVEAL-2
- Phase 3 clinical trial to evaluate the potential benefits and safety of the subcutaneously administered investigational drug VRDN-003 for people affected by chronic TED
- https://clinicaltrials.gov/study/NCT06625398
- Recruiting participants
- VRDN-003-303
- Safety and tolerability study of subcutaneously administered investigational drug VRDN-003 for people with active or chronic TED
- https://clinicaltrials.gov/study/NCT06812325
- Recruiting participants
- REVEAL-1
Randomized, double-masked, placebo-controlled study to investigate the efficacy and safety of TOUR006 (pacibekitug) in adults with TED
Intervention:
TOUR006 (pacibekitug), a fully human monoclonal antibody against IL-6L
Delivery – subcutaneous injection
Total Number of injections – 3
Time between injections – 8 weeks
Recruiting – 81 participants
NCT Number: NCT06088979
Study Name: spiriTED
Visit: https://clinicaltrials.gov/study/NCT06088979 for more information.
Immunovant is presently recruiting for a TED clinical research study. Please use this link to learn more.
See “Understanding Thyroid Eye Disease” contributed by Immunovant.
Sling Therapeutics is now recruiting participants for a Phase 2b study to evaluate a new oral treatment for TED.